{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:28:40Z","timestamp":1775064520954,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"S8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4261,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mov Disord."],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1002\/mds.20066","type":"journal-article","created":{"date-parts":[[2004,3,12]],"date-time":"2004-03-12T08:00:52Z","timestamp":1079078452000},"page":"S129-S136","source":"Crossref","is-referenced-by-count":94,"title":["Clinical comparability of marketed formulations of botulinum toxin"],"prefix":"10.1002","volume":"19","author":[{"given":"Cristina","family":"Sampaio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\ufffdo","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004]]},"reference":[{"key":"10.1002\/mds.20066-BIB1","first-page":"94","volume":"30","author":"Kreyden","year":"2002","unstructured":"Botulinum toxin: from poison to pharmaceutical the history of a poison that became useful to mankind. 2002; 30: 94-100."},{"key":"10.1002\/mds.20066-BIB2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/mds.20066-BIB3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0041-0101(96)00070-0","volume":"34","author":"Mclellan","year":"1996","journal-title":"Toxicon"},{"key":"10.1002\/mds.20066-BIB4","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) Note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substance. CPMP\/BWP\/3207\/00."},{"key":"10.1002\/mds.20066-BIB5","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0140-6736(89)92551-8","volume":"1","author":"Quinn","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/mds.20066-BIB6","first-page":"719","volume":"87","author":"Pickett","year":"1994","journal-title":"J R Soc Med"},{"key":"10.1002\/mds.20066-BIB7","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) Note For Guidance on the Investigation of Bioavailability and Bioequivalence CPMP\/EWP\/QWP\/1401\/98."},{"key":"10.1002\/mds.20066-BIB8","year":"2003","unstructured":"Food Drug administration (FDA). Guidance for Industry Statistical Approaches to Establishing Bioequivalence. Available at: http:\/\/www.fda.gov\/cder\/guidance\/3616fnl.htm. Accessed January 2003."},{"key":"10.1002\/mds.20066-BIB9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0165-6147(00)01967-2","volume":"23","author":"Schellekens","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"10.1002\/mds.20066-BIB10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","volume":"59","author":"Marion","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB11","first-page":"56","volume":"10","author":"Whurr","year":"1995","journal-title":"Mov Disord"},{"key":"10.1002\/mds.20066-BIB12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000008122","volume":"43","author":"Dressler","year":"2000","journal-title":"Eur Neurol"},{"key":"10.1002\/mds.20066-BIB13","first-page":"2234","volume":"23","author":"Wohlfarth","year":"1997","journal-title":"Soc Neurosci"},{"key":"10.1002\/mds.20066-BIB14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/exnr.2000.7583","volume":"168","author":"Bigalke","year":"2001","journal-title":"Exp Neurol"},{"key":"10.1002\/mds.20066-BIB15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"Wohlfarth","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1002\/mds.20066-BIB16","first-page":"17","volume":"2","author":"Durif","year":"1995","journal-title":"Eur J Neurol"},{"key":"10.1002\/mds.20066-BIB17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/jnnp.59.1.102","volume":"59","author":"Marion","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB18","year":"2003","unstructured":"Food drug Administration (FDA). BOTOX-Botulinum toxin type A for treatment of cervical dystonia. Clinical review. Online at http:\/\/www.fda.gov\/cber\/review\/botaller122100r2p1.pdf. Accessed January 2003."},{"key":"10.1002\/mds.20066-BIB19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","volume":"249","author":"Naumann","year":"2002","journal-title":"J Neurol"},{"key":"10.1002\/mds.20066-BIB20","first-page":"6","author":"Ferreira","year":"1999","journal-title":"Eur J Neurol"},{"key":"10.1002\/mds.20066-BIB21","author":"Costa","year":"2002","unstructured":"Botulinum toxin type A therapy for cervical dystonia (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software."},{"key":"10.1002\/mds.20066-BIB22","year":"2003","unstructured":"The Cochrane Library. Available at: http:\/\/www.update-software.com\/cochrane\/. Accessed January 2003."},{"key":"10.1002\/mds.20066-BIB23","year":"2002","unstructured":"Clarke M, Oxman AD, editors. Cochrane reviewers' handbook 4.1.5 [updated April 2002]. In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. Updated quarterly."},{"key":"10.1002\/mds.20066-BIB24","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"key":"10.1002\/mds.20066-BIB25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"Odergren","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB26","first-page":"459","volume":"72","author":"Ranoux","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1002\/mds.20066-BIB28","author":"European Agency for the Evaluation of Medicinal Products (EMEA)","year":"2003","unstructured":"European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal products (CPMP) NeuroBloc. European Public Assessment Report. Online at: http:\/\/www.eudra.org\/humandocs\/Humans\/EPAR\/neurobloc\/neurobloc.htm. Accessed January 2003."},{"key":"10.1002\/mds.20066-BIB29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jnnp.73.5.604","volume":"73","author":"Dresseler","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB30","first-page":"189","volume":"94","author":"Lu","year":"1995","journal-title":"J Formos Med Assoc"},{"key":"10.1002\/mds.20066-BIB31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0168-5597(94)90150-3","volume":"93","author":"Ostergaard","year":"1994","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1002\/mds.20066-BIB32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.870060210","volume":"6","author":"Lorentz","year":"1991","journal-title":"Mov Disord"},{"key":"10.1002\/mds.20066-BIB33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1212\/WNL.39.1.80","volume":"39","author":"Gelb","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/mds.20066-BIB34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/mds.20066-BIB35","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"Greene","year":"1990","journal-title":"Neurology"},{"key":"10.1002\/mds.20066-BIB36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00002826-199008000-00011","volume":"13","author":"Koller","year":"1990","journal-title":"Clin Neuropharmacol"},{"key":"10.1002\/mds.20066-BIB37","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.53.8.640","volume":"53","author":"Blackie","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"Poewe","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jnnp.54.9.813","volume":"54","author":"Moore","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mds.20066-BIB40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000057902","volume":"47","author":"Laubis-Herrmann","year":"2002","journal-title":"Eur Neurol"},{"key":"10.1002\/mds.20066-BIB41","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","volume":"248","author":"Wissel","year":"2001","journal-title":"J Neurol"},{"key":"10.1002\/mds.20066-BIB42","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.1999.00602.x","volume":"13","author":"Annese","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1002\/mds.20066-BIB43","volume-title":"Elementary economic evaluation in health care","author":"Jefferson","year":"2000","unstructured":"Elementary economic evaluation in health care. 2nd ed. London: BMJ Books; 2000."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.20066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:31:31Z","timestamp":1625488291000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mds.20066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":43,"journal-issue":{"issue":"S8","published-print":{"date-parts":[[2004,3]]}},"URL":"https:\/\/doi.org\/10.1002\/mds.20066","relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004]]}}}